Viking Therapeutics announced that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15,… read more.
Novartis announced that the European Commission (EC) approved Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine treatment. Rhapsido is the first… read more.
Researchers report that weight-loss surgery improves outcomes for patients with obesity and chronic kidney disease by significantly reducing the risk of kidney failure, major cardiovascular events and death…. read more.
EAHP Congress Highlights Continuous piperacillin/tazobactam infusion via elastomeric pump offers a safe, cost-effective alternative to inpatient antibiotic therapy in paediatric oncology, with measurable benefits for ward capacity, healthcare… read more.
AbbVie announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18… read more.
BridgeBio Pharma, Inc. presented long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial, demonstrating sustained clinical benefit of acoramidis through Month 54 in patients with… read more.
A new scoping review from the University of Toronto reveals that caregivers of loved ones with ovarian cancer face significant emotional strain, heavy caregiving responsibilities, and limited support… read more.
Alnylam Pharmaceuticals, Inc announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026,… read more.
The FDA has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age… read more.
After public health experts declared measles eliminated in the U.S. in 2000, the U.S. Center for Disease Control and Prevention (CDC) established seven indicators of measles elimination status… read more.
The Nuffield Department of Women’s & Reproductive Health at the University of Oxford, together with Serac Healthcare Limited announces the publication of Phase 2 data in The Lancet Obstetrics and Gynaecology. The findings highlight the… read more.
The EMA’s CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Adstiladrin. Since Adstiladrin is an advanced therapy medicinal product, the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
